Vanda Pharmaceuticals Inc. (VNDA)

Vanda Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	216.11	198.77	192.64	254.38	268.68
Revenue Growth (YoY)	8.72%	3.18%	-24.27%	-5.32%	8.27%
Cost of Revenue	13.04	11.31	14.8	24.28	25.63
Gross Profit	203.06	187.46	177.84	230.1	243.05
Selling, General & Admin	237.95	146.41	112.88	136.49	124.05
Depreciation & Amortization Expenses	7.01	7.27	2.09	1.52	1.48
Research & Development	109.27	74.43	76.82	85.77	75.36
Total Operating Expenses	354.23	228.12	191.8	223.77	200.89
Operating Income	-151.17	-40.66	-13.95	6.33	42.17
Total Non-Operating Income (Expense)	12.52	17.74	20.29	4.97	0.2
Pretax Income	-138.65	-22.92	6.34	11.3	42.36
Provision for Income Taxes	81.83	-4.02	3.83	5.03	9.21
Net Income	-220.47	-18.9	2.51	6.28	33.15
Net Income to Common	-220.47	-18.9	2.51	6.28	33.15
Net Income Growth	-	-	-60.02%	-81.07%	42.06%
Shares Outstanding (Basic)	59	58	57	56	56
Shares Outstanding (Diluted)	59	58	58	57	57
Shares Change (YoY)	1.34%	1.03%	1.01%	0.11%	3.14%
EPS (Basic)	-3.74	-0.33	0.04	0.11	0.60
EPS (Diluted)	-3.74	-0.33	0.04	0.11	0.58
EPS Growth	-	-	-63.64%	-81.03%	38.09%
Shares Outstanding	59.1	58.31	57.53	56.78	55.9
Free Cash Flow	-110.44	-16.25	12.42	31.31	63.66
Free Cash Flow Growth	-	-	-60.33%	-50.83%	27.38%
Free Cash Flow Per Share	-1.87	-0.28	0.22	0.55	1.12
Gross Margin	93.96%	94.31%	92.32%	90.45%	90.46%
Operating Margin	-69.95%	-20.46%	-7.24%	2.49%	15.69%
Profit Margin	-102.02%	-9.51%	1.30%	2.47%	12.34%
FCF Margin	-51.10%	-8.17%	6.45%	12.31%	23.69%
EBITDA	-139.25	-30.86	-9.62	9.06	45.01
EBITDA Margin	-64.44%	-15.53%	-4.99%	3.56%	16.75%
EBIT	-151.17	-40.66	-13.95	6.33	42.17
EBIT Margin	-69.95%	-20.46%	-7.24%	2.49%	15.69%
Effective Tax Rate	-59.02%	17.54%	60.42%	44.47%	21.74%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q